226 related articles for article (PubMed ID: 37355548)
1. Dissecting Interleukin-6 Classic and Trans-signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2023; 2691():207-224. PubMed ID: 37355548
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Interleukin-6 Classic- and Trans-Signaling in Inflammation and Cancer.
Garbers C; Rose-John S
Methods Mol Biol; 2018; 1725():127-140. PubMed ID: 29322414
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Chalaris A; Schmidt-Arras D; Yamamoto K; Rose-John S
Dig Dis; 2012; 30(5):492-9. PubMed ID: 23108305
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 and its receptors: a highly regulated and dynamic system.
Wolf J; Rose-John S; Garbers C
Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
[TBL] [Abstract][Full Text] [Related]
5. The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation.
Rose-John S
Clin Pharmacol Ther; 2017 Oct; 102(4):591-598. PubMed ID: 28675418
[TBL] [Abstract][Full Text] [Related]
6. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.
Rose-John S
Int J Biol Sci; 2012; 8(9):1237-47. PubMed ID: 23136552
[TBL] [Abstract][Full Text] [Related]
7. The balance of interleukin (IL)-6, IL-6·soluble IL-6 receptor (sIL-6R), and IL-6·sIL-6R·sgp130 complexes allows simultaneous classic and trans-signaling.
Baran P; Hansen S; Waetzig GH; Akbarzadeh M; Lamertz L; Huber HJ; Ahmadian MR; Moll JM; Scheller J
J Biol Chem; 2018 May; 293(18):6762-6775. PubMed ID: 29559558
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 controls recycling and degradation, but not internalization of its receptors.
Flynn CM; Kespohl B; Daunke T; Garbers Y; Düsterhöft S; Rose-John S; Haybaeck J; Lokau J; Aparicio-Siegmund S; Garbers C
J Biol Chem; 2021; 296():100434. PubMed ID: 33610555
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic control of Interleukin-11 and Interleukin-6 biology.
Lokau J; Agthe M; Flynn CM; Garbers C
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2105-2117. PubMed ID: 28630024
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130.
Tenhumberg S; Waetzig GH; Chalaris A; Rabe B; Seegert D; Scheller J; Rose-John S; Grötzinger J
J Biol Chem; 2008 Oct; 283(40):27200-7. PubMed ID: 18650419
[TBL] [Abstract][Full Text] [Related]
12. Blocking only the bad side of IL-6 in inflammation and cancer.
Rose-John S
Cytokine; 2021 Dec; 148():155690. PubMed ID: 34474215
[TBL] [Abstract][Full Text] [Related]
13. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers.
Rose-John S; Schooltink H
Recent Results Cancer Res; 2007; 174():57-66. PubMed ID: 17302185
[TBL] [Abstract][Full Text] [Related]
14. Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.
Wolf J; Waetzig GH; Chalaris A; Reinheimer TM; Wege H; Rose-John S; Garbers C
J Biol Chem; 2016 Jul; 291(31):16186-96. PubMed ID: 27226573
[TBL] [Abstract][Full Text] [Related]
15. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling.
Baran P; Nitz R; Grötzinger J; Scheller J; Garbers C
J Biol Chem; 2013 May; 288(21):14756-68. PubMed ID: 23564454
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of IL-6 trans-signaling by a miniaturized, optimized chimeric soluble gp130 inhibits T
Heise D; Derrac Soria A; Hansen S; Dambietz C; Akbarzadeh M; Berg AF; Waetzig GH; Jones SA; Dvorsky R; Ahmadian MR; Scheller J; Moll JM
Sci Signal; 2021 Aug; 14(696):. PubMed ID: 34404751
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
Rose-John S; Scheller J; Elson G; Jones SA
J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor.
Garbers C; Thaiss W; Jones GW; Waetzig GH; Lorenzen I; Guilhot F; Lissilaa R; Ferlin WG; Grötzinger J; Jones SA; Rose-John S; Scheller J
J Biol Chem; 2011 Dec; 286(50):42959-70. PubMed ID: 21990364
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
20. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer.
Rose-John S
FEBS Lett; 2022 Mar; 596(5):557-566. PubMed ID: 34738234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
